Variations of percentages and absolute numbers of T cell subsets in patients with rheumatoid arthritis after treatment with abatacept. Numbers in 2nd line of each box are absolute numbers (cell/μl).
| Lymphocyte Subtype | Baseline | 48 Weeks | |
|---|---|---|---|
| CD3+CD4+ % of total lymphocyte | 59.2 (46.9–70.3) | 63.3 (51.1–70.4) | 0.472 |
| No. cells | 749 (322–1773) | 851 (328–1438) | 0.937 |
| CD3+CD4+ naïve % of total CD3+CD4+ | 37.2 (22.1–38.9) | 33.1 (21.8–36.8) | 0.556 |
| No. cells | 216 (135–445) | 325 (148–446) | 0.790 |
| CD3+CD4+ CM % of total CD3+CD4+ | 41.1 (34.5–44.6) | 54.1 (42.1–57.2) | 0.061 |
| No. cells | 292 (200–411) | 466 (316–702) | 0.473 |
| CD3+CD4+ EM % of total CD3+CD4+ | 20.3 (14.7–25.1) | 14.7 (10.5–17.6) | 0.519 |
| No. cells | 149 (113–227) | 124 (87–153) | 0.399 |
| CD3+CD4+ TDEM % of total CD3+CD4+ | 1.25 (0.6–2.5) | 0.8 (0.5–1.6) | 0.270 |
| No. cells | 12 (5–22) | 6 (4–12) | 0.449 |
| CD3+CD4+ EFF TOT % of total CD3+CD4+ | 21.5 (15.4–31.2) | 16 (10.8–18.8) | 0.352 |
| No. cells | 163 (129–261) | 135 (93–159) | 0.296 |
| CD3+CD4+CD28+ % of total CD3+CD4+ | 95.2 (84.9–95.9) | 96.9 (90.3–98.6) | 0.349 |
| No. cells | 680 (446–879) | 825 (510–1162) | 0.954 |
| CD3+CD4+CD28– % of total CD3+CD4+ | 4.8 (4.1–15.1) | 3.0 (1.4–9.7) | 0.349 |
| No. cells | 49 (32–75) | 20 (15–27) | 0.257 |
| CD3+CD8+ % of total lymphocyte | 20.4 (13.0–28.6) | 21.4 (13.0–27.9) | 0.941 |
| No. cells | 188 (128–581) | 288 (79–502) | 0.927 |
| CD3+CD8+ naïve % of total CD3+CD8+ | 18.6 (12.6–31.8) | 27.2 (20.6–35.0) | 0.342 |
| No. cells | 48 (23–91) | 88 (29–160) | 0.304 |
| CD3+CD8+ CM % of total CD3+CD8+ | 11.5 (7.1–13.7) | 22.3 (15.6–32.5) | 0.002 |
| No. cells | 29 (15–43) | 44 (17–117) | 0.128 |
| CD3+CD8+ EM % of total CD3+CD8+ | 29.9 (23.2–42.2) | 26.8 (20.9–33.7) | 0.377 |
| No. cells | 81 (57–121) | 64 (37–86) | 0.276 |
| CD3+CD8+ TDEM % of total CD3+CD8+ | 32.0 (20.4–41.3) | 21.8 (9.7–25.7) | 0.033 |
| No. cells | 72 (52–112) | 26 (17–48) | 0.132 |
| CD3+CD8+ EFF TOT % of total CD3+CD8+ | 68.7 (54.5–78.6) | 49.3 (31.4–58.8) | 0.040 |
| No. cells | 170 (108–234) | 85 (61–132) | 0.138 |
| CD3+CD8+CD28+ % of total CD3+CD8+ | 61.3 (37.7–75.1) | 77.6 (74.0–87.6) | 0.009 |
| No. cells | 124 (85–267) | 249 (99–400) | 0.528 |
| CD3+CD8+CD28– | 38.7 (24.9–62.3) | 22.3 (12.1–25.9) | 0.008 |
| No. cells | 109 (85–145) | 32 (30–41) | 0.055 |